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Titrimetric and spectrophotometric methods are described for the determination of oxcarbazepine (OXC) in bulk drug and in
tablets. The methods use N-bromosuccinimide (NBS) and bromopyrogallol red (BPR) as reagents. In titrimetry (method A),
an acidiﬁed solution of OXC is titrated directly with NBS using methyl orange as indicator. Spectrophotometry (method B)
involves the addition of known excess of NBS to an acidiﬁed solution of OXC followed by the determination of the unreacted
NBS by reacting with BPR and measuring the absorbance of the unreacted dye at 460nm. Titrimetry allows the determination
of 6–18mg of OXC and follows a reaction stoichiometry of 1:1 (OXC:NBS), whereas spectrophotometry is applicable over the
concentration range of 0.8–8.0μgmL −1. Method B with a calculated molar absorptivity of 2.52 × 104 Lmol −1 cm−1 is the most
sensitive spectrophotometric method ever developed for OXC. The optical characteristics such as limits of detection (LOD),
quantiﬁcation (LOQ), and Sandell’s sensitivity values are also reported for the spectrophotometric method. The accuracy and
precision of the methods were studied on intraday and interday basis. The methods described could usefully be applied to routine
quality control of tablets containing OXC. No interference was observed from common pharmaceutical adjuvants. Statistical
comparison of the results with a reference method shows an excellent agreement and indicates no signiﬁcant diﬀerence in accuracy
and precision. The reliability of the methods was further ascertained by recovery studies in standard addition procedure.
1.Introduction
Oxcarbazepine (OXC), (chemically known as 10,11-dihydro-
10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide), is a novel
antiepileptic drug, which was developed as a second gen-
eration and a follow-up compound to carbamazepine.
Clinically, it has been used to treat several types of epilepsy
[1–3] and bipolar disorders [4].
The ever-increasing use of OXC in pharmaceutical
formulations has necessitated its determination as a matter
of foremost importance. OXC is not oﬃcial in any Phar-
macopoeia. Various analytical methods such as HPLC [5–
8], HPTLC [9], GC [8], microemulsion electrokinetic chro-
matography [10], capillary electrokinetic chromatography
[11], voltammetry [12, 13] and capillary electrophoresis
[14] have been reported for the determination of OXC in
pharmaceuticals. However, these methods involve the use of
expensive instruments which are not available at most qual-
ity control laboratories in developing and underdeveloped
nations.
Titrimetry is still widely used in analytical chemistry
for its superior speed and simplicity with little sacriﬁce
in accuracy and precision. OXC is present in relatively
large amounts (150 to 600mg per tablet) in pharmaceutical
formulations. The simplicity and rapidity of titrimetry is
more advantageous especially for macroanalysis over any
instrumental methods. Since there is no stringent conditions
to be maintained, more precise and accurate results are
obtained from titrimetry. Because of one or the other advan-
tage of titrimetry, it is widely applicable for the assay of many
pharmaceutical compounds in many Pharmacopoeias. On
the other hand, the spectrophotometric technique continues2 International Journal of Analytical Chemistry
to be used in the assay of diﬀerent classes of drugs in pure
and in pharmaceutical formulations [15–18].
Despite being one of the most widely used antiepileptic
drugs, no titrimetric method has been reported for OXC,
and even a few visible spectrophotometric methods reported
[19–21]s u ﬀer from one or another disadvantage. Of the
two methods reported by Gandhimathi and Ravi [19],
the ﬁrst method uses Folin-Ciocalteu’s (F-C) reagent in
alkaline medium in which blue chromogen measured at
760nm, whereas the second method involves addition of
a ﬁxed volume of 3-methyl-2-benzothiazolinone hydrazine
hydrochloride (MBTH) after treating of OXC with ferric
chloride followed by the measurement of absorbance at
456nm. The methods obey Beer’s law over the linear range
of 5–30 and 10–50μgmL −1 for F-C and MBTH methods,
respectively,andthecorrespondingmolarabsorptivityvalues
are 8.06 × 103 and 3.126 × 103 Lmol −1 cm−1. In another
report [20], OXC has been determined using iron(III)
chloride and potassium hexacyanoferrate(III). The method
is based on the reduction of iron(III) ions to iron(II)
ions by drug, which in presence of hexacyanoferrate(III)
produces green coloured chromogen measurable at 770nm.
This method is applicable over the concentration range of 4–
28μgmL −1 OXC with the molar absorptivity value of 4.63 ×
103 Lmol −1 cm−1.Theyellowchromogenwithanabsorption
maximum at 430nm formed by the reaction of OXC with
methanolic KOHin DMSO medium asthebasisfortheassay
of OXC (linear range 1.0–7.0μgmL −1; molar absorptivity
1.21 × 104 Lmol −1 cm−1) has been reported by Sathish and
Nagendrappa [21].
All the four reported spectrophotometric methods are
less sensitive besides employing either organic solvent
medium or heating step.
In the present paper, we report one direct titrimetric
(method A) and one indirect spectrophotometric (method
B) methods using NBS as brominating agent in sulphuric
acid medium for the assay of OXC. In titrimetry, the
acidic solution of OXC was titrated with NBS in sulphuric
acid medium. In spectrophotometry, for the ﬁrst time,
bromopyrogallol red (BPR) has been used to determine the
unreacted NBS after completion of the reaction between
OXC and NBS in sulphuric acid medium. The proposed
methods are simple, highly accurate, and can be readily
applied to the determination of OXC in bulk drug and in
tablets.
2. Experiment
2.1. Apparatus. A Systronics model 106 digital spectropho-
tometer with 1cm path length matched quartz cells was used
to record the absorbance values.
2.2. Reagents and Standards. All chemicals used were of
analyticalreagentgrade.Distilledwaterwasusedthroughout
the investigation.
Acetic acid (2:3 and 1:9v/v) and sulphuric acid (10M)
were prepared by diluting appropriate volumes of their
concentrated acids (99% glacial acetic acid and 98% sul-
phuric acid -both from Merck, Mumbai, India) with water.
Two brands of tablets namely, Trioptal-300 (Novartis India
Ltd, Mumbai, India) and Oxetol-600 (Sun Pharmaceuticals,
Sikkim) were purchased from local commercial sources.
2.2.1. N-Bromosuccinimide (0.01M and 120μgmL −1). An
approximately 0.01M solution was prepared by dissolving
an accurately weighed quantity of NBS (Loba Chemie Ltd,
Mumbai, India, assay 99) in water with the aid of heat.
The solution was cooled to room temperature, standardized
iodometrically, kept in an ambered coloured bottle, and
storedat4
◦C.FormethodB,NBSsolutionafterstandardiza-
tion was diluted with water to get a working concentration of
120μgmL −1.
2.2.2. Bromopyarogallol Red (BPR) (0.03%). An aqueous
0.03% BPR solution was prepared daily afresh by dissolving
an accurately weighed 30mg of the dye (Loba Chemie,
Mumbai, India, purity 99%) in 10mL of methanol in a
100mL volumetric ﬂask, and the volume was made upto the
mark with water.
2.2.3. Standard OXC Solution. A stock standard solution
containing 2mgmL−1 OXC was prepared by dissolving
200mg of pure OXC (Jubilant Organosys Ltd, Nanjangud,
Mysore, India, purity 99.5%) in 40mL of glacial acetic acid;
thevolumewasbroughtto100mLwithwaterinavolumetric
ﬂask and used for assay in method A.
A 100μgmL −1 OXC standard solution was also prepared
by dissolving an accurately weighed 10mg of pure OXC in
10mL of glacial acetic acid and diluting to the mark with
water in a 100mL calibrated ﬂask, and this was diluted with
1:9 acetic acid to get a working concentration of 20μgmL −1
OXC and used in method B.
2.3. General Analytical Procedure
2.3.1. Titrimetry (Method A). A 3–9mL aliquot of pure
drug solution containing 6–18mg of OXC was accurately
measured and transferred into a 100mL titration ﬂask. The
total volume was brought to 10mL by adding 2:3 acetic
acid. Ten mL of 10MH2SO4 was added, and the solution
titrated with 0.01M NBS using a drop of methyl orange as
indicator until the red colour disappeared. A blank titration
was run and the necessary volume corrections were made.
The amount of OXC in the measured aliquot was calculated
from:
Amount

mg

= VMw
R
n
,( 1 )
where V = volume of NBS consumed, mL, Mw = relative
molecular mass of drug (252.268), R = molar concentration
of NBS, and n is the reaction stoichiometry (number of
moles NBS reacting with each mole of OXC).
2.3.2. Spectrophotometry (Method B). Diﬀerent aliquots
(0.4–4.0mL) of standard 20μgmL −1 OXC solution wereInternational Journal of Analytical Chemistry 3
transferred into a series of 10mL volumetric ﬂasks using
a microburette, and the total volume in all the ﬂasks was
adjusted to 4mL by adding 1:9 acetic acid. To each ﬂask,
1mLeachof10MH 2SO4 and 120μgmL −1 NBS solutions
were added, the content was mixed well and kept aside for 30
min at room temperature with occasional shaking. Finally,
1mL of 0.03% BPR was added to each ﬂask and the volume
wasmadeuptomarkwithwater.Then,theabsorbanceofthe
unreacted dye was measured at 460nm against reagent blank
prepared similarly without OXC.
A standard graph was prepared by plotting absorbance
against concentration, and the unknown concentration was
read from the standard graph or computed from the
regression equation derived using Beer’s law data.
2.4. Procedure for the Analysis of Tablets
2.4.1. Method A. Twenty tablets were weighed and ﬁnely
powdered. An accurately weighed quantity of the tablet
powder equivalent to 200mg OXC was transferred into a
100mL volumetric ﬂask, and about 40mL of glacial acetic
acid was added. The content of the ﬂask was shaken for
10min, 30mL of water was added, shaken for 10 more min,
and ﬁnally the volume was completed to the mark with
water. The content was mixed well and ﬁltered through a
Whatman no. 42 ﬁlter paper. First 10mL portion of the
ﬁltrate was discarded and a suitable aliquot (say 5mL)
was then subjected to analysis by following the procedure
described earlier.
2.4.2. Method B. A quantity of tablet powder containing
10mg of OXC was transferred into a 100mL volumetric
ﬂask containing 10mL of glacial acetic acid. The content was
shaken for 5min, 50mL of water was added, and content
was mixed well and shaken again for 15 more min. The
mixture was diluted to the mark with water and ﬁltered
using Whatman no. 42 ﬁlter paper. First 10mL portion of
the ﬁltrate was discarded and the resulting tablet extract
(100μgmL −1 in OXC) was diluted to 20μgmL −1 with 1:9
acetic acid. Suitable aliquot was then subjected to analysis by
following the general procedure.
2.5. Procedures for the Analysis of Placebo Blank and Synthetic
Mixture. A placebo blank containing starch (10mg), acacia
(15mg), hydroxyl cellulose (10mg), sodium citrate (10mg),
talc (20mg), magnesium stearate (15mg) and sodium
alginate (10mg) was prepared by combining all components
to form a homogeneous mixture. A 5mg of the placebo
blank was accurately weighed and its solution was prepared
as described under “tablets”, and then subjected to analysis
by following the general procedure.
Asyntheticmixturewaspreparedbyaddinganaccurately
weighed 200mg of OXC to the placebo mentioned above.
The extraction procedure for tablets as described for method
A and method B were applied separately by taking required
quantity of synthetic mixture to prepare 2mgmL−1 and
20μgmL −1 OXC solutions, respectively. Three diﬀerent vol-
umes of the resulting synthetic mixture solution (Equivalent
N Br
O
O
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O
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Scheme 1: Hydrolysis of NBS to produce hypobromous acid/
monovalent bromine.
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Scheme2:SuggestedreactionpathwayforthebrominationofOXC.
to 6, 12 and 18mg OXC in method A; 2, 4 and 6μgmL −1
in method B) were subjected to analysis by following the
respective general procedure.
3. Chemistry
N-Bromosuccinimide contains unstably bound bromine and
is used for bromination in organic chemistry [22]. In
the reactions where NBS used as brominating agent, the
monovalent positive bromine of the NBS (the bond between
bromine and nitrogen is polarized by the two neighbouring
carbonyl groups) is responsible for bromination. The forma-
tion of the monovalent bromine due to hydrolysis of NBS is
as shown in Scheme 1.
The proposed methods are based on the bromination of
the drug by NBS in sulphuric acid medium. The suggested
reaction pathway for the bromination of OXC is given in
Scheme 2.
In the proposed titrimetric method, OXC is directly
titrated with NBS in sulphuric acid medium. The reac-
tion between OXC and NBS was found to occur in 1:1
(drug:NBS) stoichiometric ratio, and all the calculations
are based on this fact. Using 0.01M NBS, 6–18mg of
OXC was conveniently determined. In spectrophotometry,
a known excess of NBS was treated with OXC and after the
reaction between OXC and NBS ensured to be complete, the
unreacted NBS was reacted with a ﬁxed concentration of
BPR followed by the measurement of residual dye at 460nm
(Figure 1 and Scheme 3).
4. Results and Discussions
4.1. Method Development: Optimization of
Experimental Variables
4.1.1. Method A. A series of experiments was performed to
select the solvent system to dissolve OXC. The drug is not4 International Journal of Analytical Chemistry
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Figure 1:AbsorptionspectraofBPRinsulphuricacid mediumand
the reagent blank (bromoderivative of the dye, BPR).
soluble in any of the solvents like water, HCl, H2SO4,H N O 3,
and H3PO4 except acetic and perchloric acids. The titration
was not feasible in perchloric acid medium. The titration
was performed in the presence of diﬀerent volumes and
diﬀerent concentrations of perchloric acid. No consistent
stoichiometry was obtained at any volume/concentration of
perchloric acid. At very high concentrations of perchloric
acid, blank consumption was more, and at lower concentra-
tions no reaction of OXC with NBS took place. The drug
solution was found to be unstable when stored for longer
time, and colloidal particles were observed when OXC was
dissolved in acetic acid of concentration lower than 2:3
(acetic acid:water). Therefore, 2:3 acetic acid was used as
solvent system.
Preliminary experiments were carried out to choose
the proper medium for the quantitative and stoichiometric
reaction between OXC and NBS. Sulphuric acid medium
yielded a consistent stoichiometry with sharp end point.
The reaction was rapid and quantitative when 8–12mL of
10 MH2SO4 in a total volume of 20mL was maintained.
When the volume was less than 8mL and greater than
12mL, slightly lower and higher stoichiometric ratios,
respectively,wereobserved. Therefore,10mLof 10MH2SO4
was used throughout the investigation. Under the optimized
reaction conditions, a deﬁnite reaction stoichiometry of 1:1
(OXC:NBS) was found for the range of 6–18mg of OXC.
4.1.2. Method B
(1) Absorption Spectra. BPR in H2SO4 medium is red in
colour and exhibited an absorption maximum at 460nm.
Addition of BPR to NBS resulted in the formation of yellow
colouredproduct(bromoderivativeofBPR)withanabsorp-
tion maximum at 390nm. OXC and NBS had no absorption
at either 460 or 390nm. When increasing concentrations
of OXC were reacted with a ﬁxed concentration of NBS
in acid medium, there occurred a concomitant decrease in
the concentration of NBS. Addition of a ﬁxed concentration
of BPR to decreasing concentrations of NBS resulted in a
proportional increase in the concentration of residual BPR
leading to a linear increase in absorbance at 460nm with
the drug concentration, which formed the basis for the
assay. Figure 1 illustrates the absorption spectra of BPR, and
the reaction product formed between NBS and BPR in the
absence of OXC (reagent blank).
(2) Selection of Reaction Medium. OXC solution in dilute
acetic acid (1:9) is stable for longer time (more than
two days) at 4
◦C. The reaction between OXC and NBS
was performed in diﬀerent acid media. Better results were
obtained in sulphuric acid medium. The eﬀect of acid
concentration on the reaction between OXC and NBS was
studied by varying the concentration of H2SO4 keeping
the concentrations of NBS and drug ﬁxed. The reaction
was found to be rapid yielding a constant absorbance
with maximum sensitivity and stability when the H2SO4
concentration was maintained in the range of 0.7–1.3M
(0.7 to 1.3mL of 10M in a total volume of 10mL).
T h es a m ea c i dc o n c e n t r a t i o nw a sf o u n ds u ﬃcient for the
instantaneous reaction between unreacted NBS and BPR. At
acid concentrations higher than 1.5 M, the solution becomes
cloudy. Therefore, 1mL of 10M H2SO4 in a total volume of
10mL was used throughout the work.
(3) Optimization of NBS. To ﬁx the optimum concentration
of NBS, diﬀerent concentrations of NBS were reacted with
a ﬁxed concentration of BPR in H2SO4 medium and the
absorbance was measured at 460nm. A constant and mini-
mum absorbance resulted with 12μgmL −1 NBS and, hence,
diﬀerent concentrations of OXC were reacted with 1mL of
120μgmL −1 NBS in H2SO4 medium before determining the
residual NBS via the reaction Scheme illustrated earlier. This
facilitated the optimization of the linear dynamic range over
which procedure could be applied for the assay of OXC.
(4) Optimization of BPR. To ﬁx the upper Beer’s law limit
with respect to BPR, diﬀerent concentrations of the dye were
reacted with a ﬁxed 1mL of 120μgmL −1 NBS in sulphuric
acid medium. After the reaction between NBS and BPR was
ensuredtobecomplete,theabsorbanceoftheunreactedBPR
w a sm e a s u r e da t4 6 0n m .I tw a sf o u n dt h a tar e p r o d u c i b l e
and minimum absorbance value was obtained when 1mL
of 0.03% BPR used. Hence, 1mL of 0.03% of BPR was used
throughout the investigation.
(5) Study of Reaction Time and Stability of the Coloured
Species. Under the described experimental conditions, the
reaction between OXC and NBS was complete within 30min
(Figure 2)a tr o o mt e m p e r a t u r e( 2 8± 2
◦C). After the
addition of BPR, the reaction between NBS and dye was
instantaneous and the absorbance of the unreacted dye was
stable for at least 45min, thereafter.International Journal of Analytical Chemistry 5
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Figure 2: Study of reaction time between NBS and OXC in
sulphuric acid medium and stability of the coloured species by
measuring the absorbance of the unreacted BPR after reacting with
NBS.
(6) Eﬀect of Diluent. In order to select proper solvent for
dilution, solvents like 1:9 acetic acid, water, methanol and
10M H2SO4 were tried. Satisfactory results were obtained
when water was used as the diluent.
4.2. Method Validation
4.2.1. Linearity and Sensitivity. Over the range investi-
gated (6–18mg), a ﬁxed reaction stoichiometry of 1:1
[OXC:NBS] was obtained in titrimetry which served as
the basis for calculations. The relationship between the
drug amount and the volume of titrant consumed was
examined. The linearity between two parameters is apparent
from the correlation coeﬃcient of 0.9955 obtained by the
method of least squares. From this, it is implied that the
reaction between OXC and NBS proceeds stoichiometrically
in the ratio 1:1 in the range studied. In spectrophotometry,
the calibration graph was found to be linear from 0.8 to
8.0μgmL −1 OXC. The measured absorbance values were
plotted versus concentration. The least square calibration
equationwasA=0.1044C−0.0113[wheretheconcentration
(C) is measured in μgm L −1] with a regression coeﬃcient
of 0.9993 (n = 5). The calculated molar absorptivity and
Sandell sensitivity values are 2.52 × 104 Lmol −1 cm−1 and
0.010μgcm −2, respectively. The limits of detection (LOD)
and quantiﬁcation (LOQ) were calculated according to the
ICH guidelines [23] using the formulae:
LOD = 3.3S/slope and LOQ = 10S/slope, (where S is the
standard deviation of the absorbance of six blank readings).
The calculated LOD and LOQ are 0.28 and 0.86μgmL −1,
respectively.
4.2.2. Accuracy and Precision. The repeatability of the pro-
posed methods was determined by performing replicate
determinations (n = 7). The intraday and interday variation
in the analysis of OXC was measured at three diﬀerent
levels. The accuracy of an analytical method expresses the
closeness between the reference value and the found value.
Accuracy was evaluated as percentage relative error between
themeasuredandtakenamounts/concentrations.Theresults
of this study are compiled in Table 1 and speak of good
intermediate precision (%RSD ≤ 3.06) and accuracy (%RE
≤ 3.75) of the results.
4.2.3.Selectivity. Intheanalysisofplaceboblank,thevolume
of NBS consumed was the same as that of the indicator
blank(methodA)andinspectrophotometry,theabsorbance
of the placebo blank was not diﬀerent from that of the
reagent blank suggesting the noninterference by the inactive
ingredients added to prepare the placebo.6 International Journal of Analytical Chemistry
Table 1: Intraday and interday accuracy and precision.
Method∗ OXC taken Intra-day accuracy and precision Inter-day accuracy and precision
OXC found RE% RSD% OXC found RE% RSD%
A
6.0 6.17 2.83 2.22 6.18 3.12 2.98
12.0 12.28 2.33 1.98 11.73 2.22 3.06
18.0 17.73 1.50 1.53 18.34 1.89 2.23
B
2.0 1.95 2.50 2.30 2.04 2.12 1.99
4.0 4.07 1.75 1.20 3.94 1.52 1.58
6.0 5.92 1.33 2.70 6.13 2.20 1.60
∗In method A, OXC taken/found are inmg and they are μgmL −1 in method B.
Table 2: Results obtained for the study of eﬀect of matrix by the
analysis of synthetic mixture.
Method∗ OXC in synthetic
mixture OXC found# %Recovery ± SD
A
6.0 5.92 98.66 ± 0.62
12.0 12.07 100.6 ± 1.22
18.0 18.56 103.1 ± 1.74
B
2.0 2.03 101.4 ± 1.56
4.0 3.96 99.11 ± 0.85
6.0 6.29 104.9 ± 1.14
∗In method A, OXC taken/found are inmg and they are μgmL −1 in method
B.
#Mean value of three determinations.
In method A, three diﬀerent aliquots of the synthetic
mixture extract were analyzed titrimetrically (n = 3i ne a c h
case), which yielded a % recovery values in the range from
98.66 to 103.1 of OXC with standard deviation values in
the range of 0.62–1.74. In spectrophotometry, three diﬀerent
aliquots of 20μgmL −1 OXC were subjected to analysis (n =
3). The recovery values of 99.11–104.9% OXC with standard
deviation 0.85−1.56 were obtained. These results which are
close to 100% recovery complement the ﬁndings of the
placeboblankanalysiswithrespecttoselectivity.Thedetailed
results are presented in Table 2.
4.2.4. Robustness and Ruggedness. To evaluate the robustness
of the methods, volume of H2SO4 was slightly altered (10
± 1mL) with reference to optimum values in titrimetry.
However, in spectrophotometry, the reaction time (after
adding NBS, time varied was 30 ± 2min) and volume
of BPR (1 ± 0.2mL of 0.03%) were slightly altered. To
check the ruggedness, analysis was performed by four
diﬀerent analysts, and on three diﬀerent burettes (method
A) or spectrophotometers (method B) by the same analyst.
The robustness and the ruggedness were checked at three
diﬀerent drug levels (6, 12, and 18mg in method A; 2, 4,
and 6μgmL −1 in method B). The intermediate precision,
expressed as percent RSD, which is a measure of robustness
and ruggedness, was within the acceptable limits (1.26–
3.15%) as shown in Table 3.
4.2.5. Application to Tablet Analysis. Commercial OXC
tablets were analyzed using the developed methods and
also by a reference published method [19]. The method
is based on spectrophotometric determination of OXC
using F-C reagent in alkaline medium. The results obtained
were compared statistically by the Student’s t-test and the
variance-ratio F-test [24]. The calculated t-a n dF-values
did not exceed the tabulated values of 2.77 (t) and 6.39
(F) at the 95 % conﬁdence level and for four degrees of
freedom, indicating close similarity between the proposed
methods and the reference method with respect to accuracy
and precision. These results are summarized in Table 4.
4.2.6. Recovery Study. To further ascertain the accuracy and
reliability of the methods, recovery experiments were per-
formed via standard-addition procedure. Preanalyzed tablet
powder was spiked (6mg in method A; 2μgmL −1 in method
B) with pure OXC at three diﬀerent levels (3, 6, and 9mg in
method A; 1, 2, and 3μgmL −1 in method B), and the total
was found by the proposed methods. Each determination
was repeated three times. The percent recovery of pure OXC
added (Table 5) was within the permissible limits indicating
the absence of interference by the inactive ingredients in the
assay.
5. Conclusions
One titrimetric and one new spectrophotometric method
weredevelopedandvalidatedforthedeterminationofoxcar-
bazepine using NBS as brominating agent. The titrimetric
method, ﬁrst to be reported for oxcarbazepine, is applicable
over a semi-micro-scale (6–18mg), and using spectropho-
tometry at a small concentration as 0.86μgmL −1 drug can
be determined with conﬁdence and with a fair degree of
accuracy and precision. The new approach of utilizing NBS
and bromopyrogallol red as reagents in spectrophotometry
is the ﬁrst of such reports. The method is the most sensitive
ever developed for oxcarbazepine, though somewhat less
rapid requiring a standing time of 30min. Both methods
are simple, accurate, and precise and are free from extreme
experimental conditions such as heating at high tempera-
ture and use of organic solvent unlike in some reported
methods. Both the methods were applied successfully to the
determination of OXC in tablets. Compared to many exist-
ing instrumental methods for oxcarbazepine, the proposed
spectrophotometric method has two additional advantages
of simplicity of operations and low-cost instrument. BothInternational Journal of Analytical Chemistry 7
Table 3: Robustness and ruggedness.
Method A Method B
OXC
studied
mg
Robustness
(RSD, %)
Ruggedness (RSD, %) OXC
studied
μgmL −1
Robustness (RSD, %) Ruggedness (RSD, %)
Conditions altered∗ Inter-analysts
(n = 4)
Inter-instruments
(n = 3) Volume of H2SO4
(n = 3)
Inter-analysis
(n = 4)
Inter-burettes
(n = 4)
Volume of BPR
(n = 3)
Reaction time
(n = 3)
6.0 3.10 2.22 2.89 2.0 3.15 1.52 2.21 1.89
12.0 2.69 1.89 2.65 4.0 3.02 2.56 1.89 1.56
18.0 2.50 1.56 2.56 6.0 2.10 1.26 2.00 2.13
∗In method A, volumes of 10M H2SO4 varied were 10 ± 1mL, In method B, volumes of BPR varied were 1 ± 0.1mL, and the reaction time employed was 30
± 2min.
Table 4: Results of analysis of tablets by the proposed methods.
Tablets analysed Label claim, mg/tablet Found∗ (Percent of label claim ± SD)
Reference method Method A Method B
Trioptal 300 300 98.14 ± 1.56
97.33 ± 0.89 98.66 ± 1.12
t = 1.04 t = 0.61
F = 3.07 F = 1.94
Oxetol 600 600 102.1 ± 1.26
101.3 ± 1.56 100.2 ± 0.93
t = 0.89 t = 2.74
F = 1.53 F = 1.84
∗Mean value of ﬁve determinations.
Table 5: Accuracy assessment by recovery experiments.
Tablets
studied
Method A Method B
OXC in
tablet, mg
Pure OXC
added,mg
Total
found,mg
Pure OXC
recovered∗,
Percent ± SD
OXC in
tablet,
μgmL −1
Pure OXC
added,
μgmL −1
Total
found,
μgmL −1
Pure OXC
recovered∗,
Percent ±
SD
Oxetol 600
6.08 3.0 9.01 97.67 ± 0.56 2.00 1.00 3.02 101.6 ± 1.12
6.08 6.0 12.43 105.83 ± 1.78 2.00 2.00 4.01 100.6 ± 0.88
6.08 9.0 14.78 96.67 ± 0.58 2.00 3.00 5.14 104.5 ± 1.45
∗Mean value of three determinations.
the methods make use of very easily available and cheaper
reagents which demonstrates their cost-eﬀectiveness. These
advantageous features advocate their use in quality control
laboratories for routine use.
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